START-UP’s 2013 Life Science Venture Capital Survey: Lights, Even Exits, At The End Of A Dark Tunnel
This article was originally published in Start Up
Executive Summary
Our third annual survey of institutional and corporate VCs arrives as life science investing reaches a crossroads. Public markets are gung ho for new biotech companies, lifting the spirits of a subset of our respondents, but VCs still face big hurdles to raise new funds.